The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity
Abstract
Three new monoclonal antibodies (MAbs) (MOv16, MOv18 and MOv19) were raised against human ovarian carcinoma. To obtain more specific reagents than those produced so far, we adopted the following experimental approach which consisted of: (1) the selection of a poorly differentiated ovarian carcinoma which was unreactive with all the MAb previously selected in our laboratory; and (2) the application of a particular immunization protocol. The reactivity of the selected MAbs was studied by solid‐phase RIA on live and fixed cells from tumor cell lines and by immunofluorescence on frozen sections from surgical specimens. The MAb MOv16 reacted with 60% of ovarian carcinomas as well as with a high percentage of other carcinomas and with some normal tissues. In contrast, MOv18 and MOv19 appeared to have restricted specificities for ovarian carcinomas and cystadenomas. Reactivity on other carcinomas was only observed in a few cases and no reactivity was found on non‐epithelial tumors or normal tissues. Immunoprecipitation experiments indicated that MOv16 recognizes a 48‐50‐kDA protein, whereas MOv18 and MOv19 both identify a 38‐40 kDA glycoprotein band. Cross‐competition experiments, together with a double‐determinant immunoradiometric assay which uses MOv18 as catcher and MOv19 as tracer, suggested that they recognize different epitopes carried by the same molecule. The affinity constants of MOv18 and MOv19 were estimated to be in the range of 10 8 ‐ 10 9 M‐1. Taken together, the properties of these antibodies, their restricted ovarian tumor specificities and relative high affinity constants, suggest that they could represent promising tools for in vivo applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose
Ey, P. L., Prowse, S. J., & Jenkin, C. R. (1978) · Immunochemistry · doi:10.1016/0161-5890(78)90070-6 · Cited by 2,685
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
Magnani, J. L., Steplewski, Z., Koprowski, H., & Ginsburg, V. (1983) · PubMed · Cited by 589
The kinetics of antibody binding to membrane antigens in solution and at the cell surface
Mason, D. W., & Williams, A. F. (1980) · Biochemical Journal · doi:10.1042/bj1870001 · Cited by 567
Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.
Johnson, V. G., Schlom, J., Paterson, A. J., Bennett, J., Magnani, J. L., & Colcher, D. M. (1986) · PubMed · Cited by 406
Burchell, J., Durbin, H., & Taylor-Papadimitriou, J. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.1.508 · Cited by 333
Generation of monoclonal antibodies reacting with normal and cancer cells of human breast.
Ménard, S., Tagliabue, E., Canevari, S., Fossati, G., & COLNAGHI, M. I. (1983) · PubMed · Cited by 231
Self-citation
Cited by
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationParker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Elnakat, H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.001 · Cited by 649
Exploiting the folate receptor α in oncology
Scaranti, M., Cojocaru, E., Banerjee, S., & Banerji, U. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0339-5 · Cited by 593
Overexpression of folate binding protein in ovarian cancers
Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., & Boiocchi, M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970422)74:2<193::aid-ijc10>3.0.co;2-f · Cited by 521
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Dendrimers in Oncology: An Expanding Horizon
Tekade, R. K., Kumar, P. V., & Jain, N. K. (2009) · Chemical Reviews · doi:10.1021/cr068212n · Cited by 466
Folate-targeted therapies for cancer
Xia, W., & Low, P. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100509v · Cited by 448
Targeting folate receptor alpha for cancer treatment
Cheung, A., Bax, H. J., Josephs, D. H., Ilieva, K. M., Pellizzari, G., Opzoomer, J., Bloomfield, J., Fittall, M., Grigoriadis, A., Figini, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9651 · Cited by 430
Self-citationTargeted drug delivery via folate receptors
Zhao, X., Li, H., & Lee, R. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.309 · Cited by 358
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355
The folate receptor: What does it promise in tissue-targeted therapeutics?
Salazar, M. D., & Ratnam, M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9048-0 · Cited by 350
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Stepan, L. P., Trueblood, E. S., Hale, K., Babcook, J., Borges, L., & Sutherland, C. L. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410430 · Cited by 271
Chang, K., Pastan, I., & Willingham, M. C. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500308 · Cited by 271
Hwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., & Eshhar, Z. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.361 · Cited by 256
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy
Smith, J. B., Lanitis, E., Dangaj, D., Buza, E., Poussin, M., Stashwick, C., Scholler, N., & Powell, D. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.149 · Cited by 58
“The MOV19 CAR, specific for human FR α [33], was utilized as a positive control for tumor-specific reactivity (Figure 1a, bottom).”
Metadata
- Authors
- Miotti, S., Canevari, S., Ménard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., & Colnaghi, M. I.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1987-03-15
- Volume
- 39
- Issue
- 3
- Pages
- 297-303
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2064525881
- Cited by
- 315
- References
- 8
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.